GSK plc and Bora Pharmaceuticals have renewed their long‑standing partnership with a $250 million, five‑year global manufacturing contract that will see Bora manufacture a broad portfolio of GSK products across multiple sites worldwide.
Under the agreement, Bora will produce GSK’s medicines in a range of therapeutic areas—including HIV, malaria, pneumonia, parasitic infections, depression, migraine, acne, eczema and psoriasis—leveraging its capabilities in oral solids, semi‑solids, liquids, biologics and sterile injectables.
The renewal extends the collaboration that began when Bora acquired a GSK facility in 2020, giving Bora a predictable, recurring revenue stream and reinforcing its position as a leading contract development and manufacturing organization (CDMO).
For GSK, the deal supports its strategy to deepen global production capabilities and enhance supply‑chain resilience. The contract follows a strong 2025 year in which total sales reached £32.7 billion and core operating profit grew 11 %. GSK reaffirmed 2026 guidance of 3‑5 % revenue growth and 7‑9 % core operating profit growth, underscoring confidence in its specialty‑medicine focus.
The partnership provides Bora with stable revenue that can fund expansion of its manufacturing footprint, while allowing GSK to focus on R&D and commercialization. Together, the companies signal a commitment to flexible, scalable manufacturing solutions that can meet evolving market demand.
GSK CEO Luke Miels highlighted the company’s robust 2025 performance and confidence that the momentum will continue into 2026, emphasizing the importance of commercial launches and accelerated R&D. Bora Chair and CEO Bobby Sheng noted the decade‑long collaboration and expressed gratitude for the opportunity to support GSK’s mission. Bora CDMO President J.D. Mowery underscored that strong partnerships like this are foundational to Bora’s growth and reflect its execution excellence.
The renewal, extending through 2030, strengthens both companies’ positions in the specialty‑medicine market and demonstrates confidence in a long‑term, mutually beneficial relationship.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.